A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer

Davide Serrano; Matteo Lazzeroni; Sara Gandini; Debora Macis; Harriet Johansson; Jennifer Gjerde; Ernst Lien; Irene Feroce; Giancarlo Pruneri; Maria Teresa Sandri; Fabio Bassi; Fabricio Brenelli; Alberto Luini; Massimiliano Cazzaniga; Clara Varricchio; Aliana Guerrieri-Gonzaga; Andrea DeCensi; Bernardo Bonanni

doi:10.1186/bcr3439

A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer

Breast Cancer Research ◽

10.1186/bcr3439 ◽

2013 ◽

Vol 15 (3) ◽

Cited By ~ 12

Author(s):

Davide Serrano ◽

Matteo Lazzeroni ◽

Sara Gandini ◽

Debora Macis ◽

Harriet Johansson ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase Ii ◽

Low Dose ◽

Premenopausal Women ◽

Randomized Phase Ii ◽

Estrogen Receptor Positive ◽

Positive Breast Cancer

Download Full-text

A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG07): The efficacy and its correlation with circulating endothelial cells.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.618 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 618-618

Author(s):

T. Ueno ◽

N. Masuda ◽

S. Kamigaki ◽

T. Morimoto ◽

S. Nakamura ◽

...

Keyword(s):

Breast Cancer ◽

Endothelial Cells ◽

Estrogen Receptor ◽

Phase Ii ◽

Low Dose ◽

Phase Ii Trial ◽

Circulating Endothelial Cells ◽

Multicenter Phase ◽

Estrogen Receptor Positive ◽

Positive Breast Cancer

Download Full-text

Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: A randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy

The Breast ◽

10.1016/j.breast.2013.03.002 ◽

2013 ◽

Vol 22 (3) ◽

pp. 263-267 ◽

Cited By ~ 11

Author(s):

Takashi Hojo ◽

Takayuki Kinoshita ◽

Shigeru Imoto ◽

Chikako Shimizu ◽

Hirotsugu Isaka ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Endocrine Therapy ◽

Phase Ii ◽

Phase Ii Trial ◽

Randomized Phase Ii ◽

Optimal Duration ◽

Estrogen Receptor Positive ◽

Post Menopausal ◽

Positive Breast Cancer

Download Full-text

Faculty Opinions recommendation of Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734565867.793581155 ◽

2020 ◽

Author(s):

David Potter

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Neoadjuvant Therapy ◽

Early Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Estrogen Receptor Positive

Download Full-text

Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor–Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial

Journal of Nuclear Medicine ◽

10.2967/jnumed.117.194654 ◽

2017 ◽

Vol 59 (2) ◽

pp. 197-203 ◽

Cited By ~ 12

Author(s):

Michel Paquette ◽

Éric Lavallée ◽

Serge Phoenix ◽

René Ouellet ◽

Helena Senta ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Estrogen Receptor ◽

Cancer Patients ◽

Phase Ii ◽

The Novel ◽

Breast Cancer Patients ◽

Estrogen Receptor Positive ◽

Ongoing Phase ◽

Positive Breast Cancer

Download Full-text

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

Cancer Medicine ◽

10.1002/cam4.2423 ◽

2019 ◽

Vol 8 (12) ◽

pp. 5468-5481

Author(s):

Nobuaki Sato ◽

Norikazu Masuda ◽

Takashi Morimoto ◽

Takayuki Ueno ◽

Chizuko Kanbayashi ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase Ii ◽

Phase Ii Study ◽

Open Label ◽

Estrogen Receptor Positive ◽

Open Label Phase ◽

Positive Breast Cancer

Download Full-text

Abstract GS2-07: MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer

10.1158/1538-7445.sabcs17-gs2-07 ◽

2018 ◽

Cited By ~ 9

Author(s):

P Schmid ◽

M Zaiss ◽

C Harper-Wynne ◽

M Ferreira ◽

S Dubey ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Mtor Inhibitor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Estrogen Receptor Positive

Download Full-text

Abstract PD1-10: Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693)

10.1158/1538-7445.sabcs18-pd1-10 ◽

2019 ◽

Cited By ~ 1

Author(s):

WR Parulekar ◽

AA Joy ◽

K Gelmon ◽

M Mates ◽

C Desbiens ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Endocrine Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Second Line ◽

Randomized Phase Ii ◽

Estrogen Receptor Positive

Download Full-text

Randomized pre-operative study of 750 mg of fulvestrant and 20 mg tamoxifen in premenopausal women with estrogen receptor-positive breast cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(06)80373-3 ◽

2006 ◽

Vol 4 (2) ◽

pp. 150-151

Author(s):

O. Young ◽

Renshaw ◽

S. White ◽

J. Macaskill ◽

D. Cameron ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Premenopausal Women ◽

Estrogen Receptor Positive ◽

Positive Breast Cancer

Download Full-text

Adjuvant!© Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-010-0794-2 ◽

2010 ◽

Vol 123 (1) ◽

pp. 303-310 ◽

Cited By ~ 17

Author(s):

Robert J. Paridaens ◽

Shari Gelber ◽

Bernard F. Cole ◽

Richard D. Gelber ◽

Beat Thürlimann ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Ovarian Function ◽

Premenopausal Women ◽

Online Estimation ◽

Ovarian Function Suppression ◽

Estrogen Receptor Positive ◽

Positive Breast Cancer

Download Full-text

A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-017-4199-3 ◽

2017 ◽

Vol 163 (3) ◽

pp. 535-544 ◽

Cited By ~ 9

Author(s):

José Baselga ◽

Serafin M. Morales ◽

Ahmad Awada ◽

Joanne L. Blum ◽

Antoinette R. Tan ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase Ii ◽

Phase Ii Study ◽

Estrogen Receptor Positive ◽

Positive Breast Cancer

Download Full-text